This is a ready-to-use validation protocol for a trace-level method, an ICP-MS elemental impurity method under ICH Q3D and USP <233>, or an LC-MS/MS or GC-MS/MS nitrosamine or NDSRI method under the current FDA and EMA nitrosamine guidance and ICH M7(R2). It is not a substitute for the general assay/impurity validation protocol; use it alongside that protocol when the method’s acceptance limit is a permitted daily exposure or an acceptable intake rather than a percentage of label claim, because that single difference changes where the accuracy spike and the LOQ confirmation have to sit. Replace every <<FILL: ...>> placeholder, set your document numbers, and route this through document control for approval before any validation data are generated. A filled specimen follows. Confirm every cited chapter and guidance against its current published version before you rely on it. This is general educational content to adapt, not regulatory advice.
Approval page
| Role | Name | Signature | Date |
|---|---|---|---|
| Author (method owner / analytical development) | <<FILL>> | ||
| Reviewer (QC laboratory) | <<FILL>> | ||
| Reviewer (Toxicology, for the limit basis) | <<FILL>> | ||
| Approver (Quality Assurance) | <<FILL>> |
Document control header
| Field | Entry |
|---|---|
| Document title | Trace-level method validation: <<FILL: method name>> for <<FILL: product / drug substance>> |
| Protocol number | <<FILL: PRT-ID>> |
| Version | <<FILL: version, e.g. 1.0>> |
| Contaminant class | <<FILL: elemental impurity (name element) / nitrosamine (name compound) / NDSRI / M7 mutagenic impurity>> |
| Platform | <<FILL: ICP-MS / ICP-OES / LC-MS/MS / GC-MS/MS>> |
| Effective date | <<FILL>> |
| Supersedes | <<FILL: prior version or "New">> |
1. Objective
To demonstrate that <<FILL: method number>> can accurately and specifically detect and quantify <<FILL: contaminant>> in <<FILL: product>> at and below the concentration limit derived from its permitted daily exposure (ICH Q3D, elemental impurities) or acceptable intake (nitrosamines, NDSRIs, M7 mutagenic impurities), against acceptance criteria defined in this protocol before any data are generated.
2. Scope
This protocol covers specificity (including isobaric or structurally related interference), accuracy at and around the limit, repeatability and intermediate precision at the limit, LOQ confirmation, and platform-specific system suitability. It assumes the limit itself, the permitted daily exposure, acceptable intake, or CPCA-category figure and the arithmetic converting it to a product concentration, was derived and approved separately; that work belongs to the ICH Q3D risk assessment or the nitrosamine acceptable-intake worksheet, not to this protocol. This protocol validates the method’s ability to see the limit, not the limit itself.
3. Method description and the limit it validates against
| Item | Detail |
|---|---|
| Technique | <<FILL: ICP-MS, ICP-OES, LC-MS/MS, GC-MS/MS>> |
| Target analyte(s) | <<FILL: element(s) by class, or named nitrosamine/NDSRI>> |
| Sample preparation | <<FILL: digestion scheme for ICP-MS/OES, or extraction/derivatization for MS/MS>> |
| Approved limit this method validates against | <<FILL: concentration, e.g. "0.08 ppm", with reference to the approved risk assessment or AI worksheet that derived it>> |
| Reference standard / calibration standard | <<FILL: identity, lot, certified concentration, traceability>> |
4. Prerequisites
- The instrument holds current qualification, including the platform-specific checks (ICP-MS mass calibration and resolution check; LC-MS/MS or GC-MS/MS mass accuracy and sensitivity check), not only a generic IQ/OQ.
- The approved limit in Section 3 is traceable to a signed risk assessment (elemental impurities) or acceptable-intake worksheet (nitrosamines/NDSRIs), not restated from memory.
- Analysts are trained on trace-level technique, including contamination-avoidance practice for ICP-MS work.
- This protocol is approved before any validation data are acquired.
5. Responsibilities
| Role | Responsibility |
|---|---|
| Method owner / analytical development | Authors this protocol, confirms the approved limit it validates against, authors the report |
| Toxicology | Confirms the limit cited in Section 3 is the current approved figure before the protocol is approved |
| QC analyst | Executes studies, records raw data contemporaneously, flags any suspected contamination or carryover |
| Quality Assurance | Approves the protocol before execution, assesses deviations, approves the report |
6. System suitability (platform-specific)
| Platform | Check | Acceptance criterion |
|---|---|---|
| ICP-MS | Mass calibration / resolution | <<FILL: per instrument SOP>> |
| ICP-MS | Interference check standard (e.g. chloride-argon on arsenic, if relevant to the matrix) | <<FILL: recovery within stated range>> |
| LC-MS/MS or GC-MS/MS | Mass accuracy / sensitivity check standard | <<FILL: per instrument SOP>> |
| Either platform | Blank / carryover check | No target-analyte signal above <<FILL: fraction of LOQ>> in the blank following the highest-concentration standard |
If system suitability fails, the sequence is invalid and its data are not used.
7. Validation studies, designs, and acceptance criteria
7.1 Specificity against isobaric or structural interference
Design. For ICP-MS: identify and test for known spectral overlaps relevant to the sample matrix and the target element’s mass (for example a chloride-argon interference on arsenic, or a matrix-derived doubly charged ion overlapping a target mass). For nitrosamine or NDSRI methods: challenge the method with the drug substance itself and with structurally related process impurities and degradants, not only with a blank and placebo, because an NDSRI is by definition structurally close to its own API.
Acceptance criteria. No interference-derived signal at the target mass or retention time above <<FILL: fraction of LOQ, e.g. 10 percent>> from the matrix-interference check (ICP-MS) or from the drug substance and related compounds (MS/MS). A method relying on a generic multi-analyte nitrosamine panel must additionally demonstrate it resolves the specific NDSRI named in Section 3, not only the classic small-molecule nitrosamines the panel was originally built for.
| Interferent / related compound challenged | Result | Pass/Fail |
|---|---|---|
<<FILL>> | <<FILL>> | <<FILL>> |
7.2 Accuracy at the limit
Design. Spike at <<FILL: 50, 100, 150>> percent of the approved limit from Section 3, not at percent label claim. Prepare at least three independent replicates at each level.
Acceptance criteria. Mean recovery <<FILL: e.g. 80-120>> percent at each level, RSD not more than <<FILL>> percent.
| Level (% of limit) | Target concentration | Recovered concentration | Recovery (%) |
|---|---|---|---|
| 50 | <<FILL>> | <<FILL>> | <<FILL>> |
| 100 | <<FILL>> | <<FILL>> | <<FILL>> |
| 150 | <<FILL>> | <<FILL>> | <<FILL>> |
7.3 Precision at the limit
Design. Repeatability: six independent preparations at the limit concentration. Intermediate precision: vary analyst and day (and instrument, where feasible).
Acceptance criteria. Repeatability RSD not more than <<FILL>> percent; pooled intermediate precision RSD not more than <<FILL>> percent, wider than a typical assay method because trace-level measurement carries more relative noise.
7.4 LOQ confirmation against the approved limit, not against a calculated estimate alone
Design. Estimate LOQ (signal-to-noise or standard-deviation/slope approach), then confirm with independently prepared samples at the stated LOQ. The LOQ must be confirmed at or below <<FILL: e.g. 30>> percent of the approved limit in Section 3, so the method has margin to actually report a result at the decision point, not merely detect its presence.
Acceptance criteria. At the confirmed LOQ: recovery <<FILL: 70-130>> percent, RSD not more than <<FILL>> percent, signal-to-noise at or above <<FILL>>.
| Parameter | Value |
|---|---|
| Approved limit (Section 3) | <<FILL>> |
Target LOQ (<= <<FILL>>% of limit) | <<FILL>> |
| Confirmed LOQ (from this study) | <<FILL>> |
| Is confirmed LOQ at or below target? | <<FILL: Yes/No; if No, the method cannot support this limit, escalate>> |
8. Deviation handling
Record any deviation from this protocol (an unplanned instrument event, a failed system suitability sequence, a contamination flag) contemporaneously, assess its impact on the study’s validity, and route through <<FILL: SOP-ID for deviations>> before the study is considered complete.
9. Summary and conclusion
State, for each study, the pre-defined acceptance criterion, the result, and the pass/fail call. State the overall conclusion: the method is, or is not, validated to detect and quantify <<FILL: contaminant>> at the approved limit of <<FILL: value>>.
10. Attachments
Raw data, calibration records, chromatograms or mass spectra, the signed risk assessment or acceptable-intake worksheet that established the limit this protocol validates against.
11. References
ICH Q3D, Guideline for Elemental Impurities (current revision). USP <232> Elemental Impurities, Limits; USP <233> Elemental Impurities, Procedures. FDA, Control of Nitrosamine Impurities in Human Drugs (current revision). ICH M7(R2), Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. ICH Q2(R2), Validation of Analytical Procedures.
Confirm the current version of each before issue.
12. Revision history
| Version | Date | Author | Summary of change |
|---|---|---|---|
<<FILL: 1.0>> | <<FILL>> | <<FILL>> | Initial issue. |
Filled specimen
A generic oral solid dosage product’s API can form an NDSRI through a secondary amine in its structure. The signed CPCA worksheet assigned an acceptable intake of 100 ng/day, and at the product’s maximum daily dose of 0.5 g, that converts to an approved limit of 0.08 ppm (the arithmetic lives in the acceptable-intake worksheet, not here).
Section 3. Platform: LC-MS/MS. Target: the named NDSRI. Approved limit: 0.08 ppm, referencing acceptable-intake worksheet AIW-2026-014.
7.1 Specificity. Challenged against the drug substance itself and two structurally related process impurities. No interference-derived signal at the NDSRI’s retention time and mass transition above 8 percent of LOQ from any of the three. Pass.
7.2 Accuracy. Spiked at 50/100/150 percent of 0.08 ppm (0.04, 0.08, 0.12 ppm), three replicates each. Mean recovery 94.2 percent at 50 percent, 98.1 percent at 100 percent, 101.3 percent at 150 percent; RSD 4.1 percent across the set. Against a criterion of 80-120 percent and RSD not more than 15 percent, pass.
7.3 Precision. Repeatability (six preps at 0.08 ppm): RSD 5.8 percent. Intermediate precision (two analysts, two days, pooled): RSD 8.9 percent. Against criteria of not more than 10 percent and not more than 15 percent respectively, pass.
7.4 LOQ confirmation. Target LOQ at or below 30 percent of 0.08 ppm, that is 0.024 ppm. Confirmed LOQ: 0.02 ppm, recovery 96 percent, RSD 7.2 percent, signal-to-noise 14. 0.02 ppm is below the 0.024 ppm target. Pass.
Section 9. All four studies pass. The method is validated to detect and quantify the named NDSRI in this product at the approved limit of 0.08 ppm, with adequate margin at the confirmed LOQ of 0.02 ppm.
Common inspection findings this protocol prevents
- Accuracy spiked at percent label claim instead of at the approved toxicology-derived limit, producing a validation that proves nothing about the method’s performance at the concentration that actually matters.
- A generic multi-nitrosamine panel method used with no specificity study confirming it resolves the product’s own NDSRI.
- An LOQ confirmed as technically detectable but sitting above, or too close to, the approved limit to give a usable margin.
- ICP-MS validation run with no documented check for matrix-specific spectral interference.
- The limit cited in the protocol traced to memory or an old risk assessment version rather than the currently approved figure.
How to adapt this protocol
- Confirm the approved limit in Section 3 against the current signed risk assessment or acceptable-intake worksheet before this protocol is approved; the limit is an input to this protocol, not something it derives.
- For an elemental impurity method, name the specific element(s) and class, and build the interference check around the real sample matrix.
- For a nitrosamine or NDSRI method, always include the drug substance and its closest structural relatives in the specificity challenge, even if a vendor or literature method claims broad applicability.
- Set the target LOQ fraction (Section 7.4) from your own risk tolerance; 30 percent of the limit is a common starting point, not a mandated number.